Research ExplorerPublicationsCOVID-19 Vaccination and Uveitis: Epidemiology, Clinical Fea...

COVID-19 Vaccination and Uveitis: Epidemiology, Clinical Features and Visual Prognosis

Standard

COVID-19 Vaccination and Uveitis: Epidemiology, Clinical Features and Visual Prognosis. / Ferrand, Nawfel; Accorinti, Massimo; Agarwal, Mamta; Spartalis, Christoph; Manni, Priscilla; Stuebiger, Nicole; Zierhut, Manfred.

In: OCUL IMMUNOL INFLAMM, Vol. 30, No. 5, 07.2022, p. 1265-1273.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Ferrand, N, Accorinti, M, Agarwal, M, Spartalis, C, Manni, P, Stuebiger, N & Zierhut, M 2022, 'COVID-19 Vaccination and Uveitis: Epidemiology, Clinical Features and Visual Prognosis', OCUL IMMUNOL INFLAMM, vol. 30, no. 5, pp. 1265-1273. https://doi.org/10.1080/09273948.2022.2058964

APA

Ferrand, N., Accorinti, M., Agarwal, M., Spartalis, C., Manni, P., Stuebiger, N., & Zierhut, M. (2022). COVID-19 Vaccination and Uveitis: Epidemiology, Clinical Features and Visual Prognosis. OCUL IMMUNOL INFLAMM, 30(5), 1265-1273. https://doi.org/10.1080/09273948.2022.2058964

Vancouver

Ferrand N, Accorinti M, Agarwal M, Spartalis C, Manni P, Stuebiger N et al. COVID-19 Vaccination and Uveitis: Epidemiology, Clinical Features and Visual Prognosis. OCUL IMMUNOL INFLAMM. 2022 Jul;30(5):1265-1273. https://doi.org/10.1080/09273948.2022.2058964

Bibtex

@article{661aa7076f8247369d6906619f61731b,
title = "COVID-19 Vaccination and Uveitis: Epidemiology, Clinical Features and Visual Prognosis",
abstract = "PURPOSE: To study the epidemiological and clinical features of uveitis post-COVID-19 vaccination.PATIENTS AND METHODS: Retrospective chart review of patients presenting with uveitis after COVID-19 vaccination in tertiary uveitis services.RESULTS: In total, 25 patients, 76% females, mean age 43.2 years, were included. Uveitis occurred after Pfizer, Moderna, Astra-Zeneca and Covaxin vaccination. Anterior uveitis was the most frequent type of uveitis (56%). History of uveitis was found in 19 cases (76%), among whom 90.9% of the tested patients developed anti-Sars-CoV-2 spike antibodies after vaccination. In a mean follow-up of 5 months, one-line decrease in visual acuity was found in 12% of patients. During post-vaccine uveitis, 15.8% of cases needed an increase in their systemic therapy. According to Naranjo score, new-onset uveitis had a higher probability of being associated with vaccination (p < .01).CONCLUSION: COVID-19 vaccination can cause uveitis but has no significant impact on the visual prognosis after resolution.",
keywords = "Adult, Female, Humans, Male, Antibodies, Viral, COVID-19/epidemiology, COVID-19 Vaccines/adverse effects, Follow-Up Studies, Prognosis, Retrospective Studies, Uveitis/chemically induced, Vaccination/adverse effects",
author = "Nawfel Ferrand and Massimo Accorinti and Mamta Agarwal and Christoph Spartalis and Priscilla Manni and Nicole Stuebiger and Manfred Zierhut",
year = "2022",
month = jul,
doi = "10.1080/09273948.2022.2058964",
language = "English",
volume = "30",
pages = "1265--1273",
journal = "OCUL IMMUNOL INFLAMM",
issn = "0927-3948",
publisher = "informa healthcare",
number = "5",

}

RIS

TY - JOUR

T1 - COVID-19 Vaccination and Uveitis: Epidemiology, Clinical Features and Visual Prognosis

AU - Ferrand, Nawfel

AU - Accorinti, Massimo

AU - Agarwal, Mamta

AU - Spartalis, Christoph

AU - Manni, Priscilla

AU - Stuebiger, Nicole

AU - Zierhut, Manfred

PY - 2022/7

Y1 - 2022/7

N2 - PURPOSE: To study the epidemiological and clinical features of uveitis post-COVID-19 vaccination.PATIENTS AND METHODS: Retrospective chart review of patients presenting with uveitis after COVID-19 vaccination in tertiary uveitis services.RESULTS: In total, 25 patients, 76% females, mean age 43.2 years, were included. Uveitis occurred after Pfizer, Moderna, Astra-Zeneca and Covaxin vaccination. Anterior uveitis was the most frequent type of uveitis (56%). History of uveitis was found in 19 cases (76%), among whom 90.9% of the tested patients developed anti-Sars-CoV-2 spike antibodies after vaccination. In a mean follow-up of 5 months, one-line decrease in visual acuity was found in 12% of patients. During post-vaccine uveitis, 15.8% of cases needed an increase in their systemic therapy. According to Naranjo score, new-onset uveitis had a higher probability of being associated with vaccination (p < .01).CONCLUSION: COVID-19 vaccination can cause uveitis but has no significant impact on the visual prognosis after resolution.

AB - PURPOSE: To study the epidemiological and clinical features of uveitis post-COVID-19 vaccination.PATIENTS AND METHODS: Retrospective chart review of patients presenting with uveitis after COVID-19 vaccination in tertiary uveitis services.RESULTS: In total, 25 patients, 76% females, mean age 43.2 years, were included. Uveitis occurred after Pfizer, Moderna, Astra-Zeneca and Covaxin vaccination. Anterior uveitis was the most frequent type of uveitis (56%). History of uveitis was found in 19 cases (76%), among whom 90.9% of the tested patients developed anti-Sars-CoV-2 spike antibodies after vaccination. In a mean follow-up of 5 months, one-line decrease in visual acuity was found in 12% of patients. During post-vaccine uveitis, 15.8% of cases needed an increase in their systemic therapy. According to Naranjo score, new-onset uveitis had a higher probability of being associated with vaccination (p < .01).CONCLUSION: COVID-19 vaccination can cause uveitis but has no significant impact on the visual prognosis after resolution.

KW - Adult

KW - Female

KW - Humans

KW - Male

KW - Antibodies, Viral

KW - COVID-19/epidemiology

KW - COVID-19 Vaccines/adverse effects

KW - Follow-Up Studies

KW - Prognosis

KW - Retrospective Studies

KW - Uveitis/chemically induced

KW - Vaccination/adverse effects

U2 - 10.1080/09273948.2022.2058964

DO - 10.1080/09273948.2022.2058964

M3 - Other (editorial matter etc.)

C2 - 35404757

VL - 30

SP - 1265

EP - 1273

JO - OCUL IMMUNOL INFLAMM

JF - OCUL IMMUNOL INFLAMM

SN - 0927-3948

IS - 5

ER -